This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goslinga, H. Articles by Bezemer, P. D. Search for Related Content PubMed PubMed Citation Articles by Goslinga, H. Articles by Bezemer, P. D.

Stroke, Vol 23, 181-188, Copyright © 1992 by American Heart Association

ARTICLES

Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke

H Goslinga, V Eijzenbach, JH Heuvelmans, E van der Laan de Vries, VM Melis, H Schmid-Schonbein and PD Bezemer
Department of Rheology, St. Lucas Hospital, Amsterdam, The Netherlands.

BACKGROUND AND PURPOSE: Hemodilution in the acute phase of ischemic stroke is still controversial. Multicenter studies have failed to demonstrate any benefit. The present study focuses attention on analysis of circulation in stroke and on individual restabilization of circulation. METHODS: The Amsterdam Stroke Study is a prospective, single-center, randomized clinical trial (n = 300). Normovolemic hemodilution is accomplished in a customized procedure by administration of 20% albumin plus crystalloids under hemodynamic and rheological monitoring in the acute phase of stroke. All patients receive general intensive care treatment and monitoring with a pulmonary artery catheter. This custom-tailored fluid therapy is guided on the basis of a target pulmonary capillary wedge pressure (12 +/- 3 mm Hg) and hematocrit (0.32 +/- 0.02). The control group receives only customized rehydration by infusion of crystalloids. RESULTS: We obtained significant (p less than 0.05) reduction in mortality at 3 months (from 27% to 16%) and an increase in independence at home (from 35% to 48%) after viscosity reduction by means of hemodilution with albumin in the subgroup with a hematocrit less than 0.45 (n = 201) (specific viscosity effect). We also obtained a significant (p less than 0.005) reduction in mortality at 3 months (from 27% to 8%) and an increase in independence (from 35% to 59%) after only rehydration with crystalloids in the subgroup with overt dehydration (hematocrit greater than or equal to 0.45; n = 51) as compared with the normal-hematocrit group without signs of dehydration (hematocrit less than 0.45; n = 103) (specific rehydration effect). CONCLUSIONS: This study may provide an explanation for the failures in former hemodilution trials and may re- establish proper hemodilution and rehydration as a valuable therapy in the acute phase of stroke, thus reducing mortality and improving independence after 3 months.

This article has been cited by other articles:

				Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259. [Full Text] [PDF]

				G. R. Haynes, T. A. Neff, R. Stocker, and D. R. Spahn Is Hydroxyethyl Starch Safe in Brain Injury? * Response Anesth. Analg., August 1, 2004; 99(2): 620 - 622. [Full Text] [PDF]

				T. Dziedzic, A. Slowik, and A. Szczudlik Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, June 1, 2004; 35(6): e156 - e158. [Abstract] [Full Text] [PDF]

				M. M. Wilkes and R. J. Navickis Patient Survival after Human Albumin Administration: A Meta-Analysis of Randomized, Controlled Trials Ann Intern Med, August 7, 2001; 135(3): 149 - 164. [Abstract] [Full Text] [PDF]

				K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]

				I. Eilig, M. Rachinsky, A. A. Artru, A. Alonchin, V. Kapuler, A. Tarnapolski, and Y. Shapira The Effect of Treatment with Albumin, Hetastarch, or Hypertonic Saline on Neurological Status and Brain Edema in a Rat Model of Closed Head Trauma Combined with Uncontrolled Hemorrhage and Concurrent Resuscitation in Rats Anesth. Analg., March 1, 2001; 92(3): 669 - 675. [Abstract] [Full Text] [PDF]

				L. Belayev, Y. Liu, W. Zhao, R. Busto, and M. D. Ginsberg Human Albumin Therapy of Acute Ischemic Stroke : Marked Neuroprotective Efficacy at Moderate Doses and With a Broad Therapeutic Window Stroke, February 1, 2001; 32(2): 553 - 560. [Abstract] [Full Text] [PDF]

				M. Davis and D. Barer Neuroprotection in acute ischaemic stroke. II: Clinical potential Vascular Medicine, August 1, 1999; 4(3): 149 - 163. [Abstract] [PDF]

				J. Berrouschot, H. Barthel, J. Koster, S. Hesse, A. Rossler, W. H. Knapp, and D. Schneider Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke : A Randomized Pilot Study Stroke, April 1, 1999; 30(4): 787 - 792. [Abstract] [Full Text] [PDF]

				F. T. Aichner, F. Fazekas, M. Brainin, W. Polz, B. Mamoli, and K. Zeiler Hypervolemic Hemodilution in Acute Ischemic Stroke : The Multicenter Austrian Hemodilution Stroke Trial (MAHST) Stroke, April 1, 1998; 29(4): 743 - 749. [Abstract] [Full Text] [PDF]

				K. Yanaka, P. J. Camarata, S. R. Spellman, D. E. McDonald, and R. C. Heros Optimal Timing of Hemodilution for Brain Protection in a Canine Model of Focal Cerebral Ischemia Stroke, May 1, 1996; 27(5): 906 - 912. [Abstract] [Full Text]

				A. Rebel, J. A. Ulatowski, K. Joung, E. Bucci, R. J. Traystman, and R. C. Koehler Regional cerebral blood flow in cats with cross-linked hemoglobin transfusion during focal cerebral ischemia Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H832 - H841. [Abstract] [Full Text] [PDF]